RTP Mobile Logo
Real-Life Decisions: Clinical Investigators Provide Their Perspectives on the Management of Multiple Myeloma, Myelodysplastic Syndromes and Acute Myeloid Leukemias
Released May 2011

Featuring Edited Proceedings and Interviews from a Case-Based Symposium Preceding the 52nd ASH Annual Meeting. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this spectrum of diseases. Determining which treatment approach is most appropriate for an individual patient requires careful consideration of unique clinical characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium held at the 2010 American Society of Hematology Annual Meeting, paired with select faculty interviews addressing many of the questions posed by live audience members, attempt to provide the perspectives of clinical investigators on evidence-based care across a diverse set of hematologic cancers. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for patients with hematologic cancer.

    LEARNING OBJECTIVES
    • Appraise recent data on therapeutic advances and changing practice standards in acute myeloid leukemia (AML)/acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS), and integrate this information into current clinical care when appropriate.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed or relapsed or refractory multiple myeloma (MM).
    • Develop an algorithm for risk-stratified induction therapy for patients with AML or APL.
    • Recall the emerging data with novel agents and combinations in the treatment of MM.
    • Offer evidence-based supportive management strategies to facilitate tolerability of and adherence to systemic treatments for AML/APL, MDS and MM.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    William I Bensinger, MD
    Professor of Medicine
    University of Washington
    Member, Fred Hutchinson
    Cancer Research Center
    Seattle, Washington

    Advisory Committee: Celgene Corporation, Genzyme Corporation, Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Consulting Agreement: ImClone Systems Incorporated; Paid Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genzyme Corporation, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation.

    Pierre Fenaux, MD
    Professor of Hematology
    Hôpital Avicenne
    University Paris 13
    Bobigny, France

    Advisory Committee: Bristol-Myers Squibb Company, Cephalon Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Consulting Agreement and Paid Research: Celgene Corporation.

    Morie A Gertz, MD
    Professor and Chair
    Department of Medicine
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Celgene Corporation, Millennium — The Takeda Oncology Company.

    Farhad Ravandi, MD
    Associate Professor of Medicine
    Department of Leukemia
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Schering-Plough Corporation; Speakers Bureau: Cephalon Inc, Eisai Inc, Novartis Pharmaceuticals Corporation.

    B Douglas Smith, MD
    Associate Professor of Oncology
    The Sidney Kimmel Comprehensive
    Cancer Center at Johns Hopkins
    Baltimore, Maryland

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; Paid Research: Eisai Inc, Infinity Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Synta Pharmaceuticals Corp.

    Ravi Vij, MD
    Associate Professor of Medicine
    Washington University School of Medicine
    Section of Stem Cell Transplant and Leukemia
    Division of Medical Oncology
    St Louis, Missouri

    Advisory Committee: Celgene Corporation, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium — The Takeda Oncology Company; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2011
    Expiration date: May 2012

Acknowledge and close

Listen to audio:
Real-Life Decisions: Clinical Investigators Provide Their Perspectives on the Management of Multiple Myeloma, Myelodysplastic Syndromes and Acute Myeloid Leukemias
Released May 2011

Featuring Edited Proceedings and Interviews from a Case-Based Symposium Preceding the 52nd ASH Annual Meeting. (Text and Audio Content)

Read print: